Which has better valuation & earnings, OCS or IVVD?

Invivyd has higher revenue and earnings than Oculis. Oculis is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oculis $1.45M 443.45 -$119.44M -$2.13 N/A Invivyd $53.43M 4.25 -$52.49M -$0.31 N/A

Is OCS or IVVD more profitable?

Invivyd has a net margin of -138.90% compared to Oculis' net margin of -8,460.67%. Invivyd's return on equity of -53.48% beat Oculis' return on equity. Company Net Margins Return on Equity Return on Assets Oculis -8,460.67% -56.78% -45.62% Invivyd -138.90% -53.48% -41.56%

Does the media favor OCS or IVVD?

In the previous week, Oculis had 8 more articles in the media than Invivyd. MarketBeat recorded 14 mentions for Oculis and 6 mentions for Invivyd. Invivyd's average media sentiment score of 0.88 beat Oculis' score of 0.53 indicating that Invivyd is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oculis 3 Very Positive mention(s) 0 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Invivyd 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, IVVD or HROW?

Harrow has higher revenue and earnings than Invivyd. Harrow is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Invivyd $53.43M 4.25 -$52.49M -$0.31 N/A Harrow $268.68M 5.22 -$5.14M -$0.41 N/A

Is IVVD or HROW more profitable?

Harrow has a net margin of -5.57% compared to Invivyd's net margin of -138.90%. Harrow's return on equity of 19.59% beat Invivyd's return on equity. Company Net Margins Return on Equity Return on Assets Invivyd -138.90% -53.48% -41.56% Harrow -5.57% 19.59% 2.26%

Does the media prefer IVVD or HROW?

In the previous week, Invivyd had 1 more articles in the media than Harrow. MarketBeat recorded 6 mentions for Invivyd and 5 mentions for Harrow. Harrow's average media sentiment score of 0.92 beat Invivyd's score of 0.88 indicating that Harrow is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Invivyd 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Harrow 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, COAG or IVVD?

Hemab Therapeutics has higher earnings, but lower revenue than Invivyd. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hemab Therapeutics N/A N/A N/A N/A N/A Invivyd $53.43M 4.25 -$52.49M -$0.31 N/A

Does the media favor COAG or IVVD?

In the previous week, Invivyd had 4 more articles in the media than Hemab Therapeutics. MarketBeat recorded 6 mentions for Invivyd and 2 mentions for Hemab Therapeutics. Hemab Therapeutics' average media sentiment score of 0.93 beat Invivyd's score of 0.88 indicating that Hemab Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hemab Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Invivyd 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is IVVD or WVE more profitable?

Invivyd has a net margin of -138.90% compared to WAVE Life Sciences' net margin of -255.70%. Invivyd's return on equity of -53.48% beat WAVE Life Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Invivyd -138.90% -53.48% -41.56% WAVE Life Sciences -255.70% -56.76% -42.80%

Does the media refer more to IVVD or WVE?

In the previous week, WAVE Life Sciences had 1 more articles in the media than Invivyd. MarketBeat recorded 7 mentions for WAVE Life Sciences and 6 mentions for Invivyd. Invivyd's average media sentiment score of 0.88 beat WAVE Life Sciences' score of 0.88 indicating that Invivyd is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Invivyd 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive WAVE Life Sciences 1 Very Positive mention(s) 4 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to IVVD or MPLT?

In the previous week, Invivyd had 4 more articles in the media than Maplight Therapeutics. MarketBeat recorded 6 mentions for Invivyd and 2 mentions for Maplight Therapeutics. Maplight Therapeutics' average media sentiment score of 0.93 beat Invivyd's score of 0.88 indicating that Maplight Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Invivyd 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Maplight Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Invivyd (IVVD) Competitors

$0.77 -0.04 (-5.23%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$0.78 +0.01 (+0.78%)

As of 06/12/2026 07:58 PM Eastern

Compare

IVVD vs. OCS, HROW, COAG, WVE, and MPLT

Should you buy Invivyd stock or one of its competitors? MarketBeat compares Invivyd with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Invivyd include Oculis (OCS), Harrow (HROW), Hemab Therapeutics (COAG), WAVE Life Sciences (WVE), and Maplight Therapeutics (MPLT). These companies are all part of the "pharmaceutical products" industry.

How does Invivyd compare to Oculis?

Oculis (NASDAQ:OCS) and Invivyd (NASDAQ:IVVD) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership, risk and media sentiment.

Invivyd has higher revenue and earnings than Oculis. Oculis is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oculis	$1.45M	443.45	-$119.44M	-$2.13	N/A
Invivyd	$53.43M	4.25	-$52.49M	-$0.31	N/A

Invivyd has a net margin of -138.90% compared to Oculis' net margin of -8,460.67%. Invivyd's return on equity of -53.48% beat Oculis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oculis	-8,460.67%	-56.78%	-45.62%
Invivyd	-138.90%	-53.48%	-41.56%

In the previous week, Oculis had 8 more articles in the media than Invivyd. MarketBeat recorded 14 mentions for Oculis and 6 mentions for Invivyd. Invivyd's average media sentiment score of 0.88 beat Oculis' score of 0.53 indicating that Invivyd is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oculis	3 Very Positive mention(s)	0 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Invivyd	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

22.3% of Oculis shares are held by institutional investors. Comparatively, 70.4% of Invivyd shares are held by institutional investors. 12.3% of Invivyd shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Oculis has a beta of 0.23, indicating that its share price is 77% less volatile than the broader market. Comparatively, Invivyd has a beta of 0.63, indicating that its share price is 37% less volatile than the broader market.

Oculis presently has a consensus target price of $38.33, indicating a potential upside of 245.66%. Invivyd has a consensus target price of $8.00, indicating a potential upside of 938.96%. Given Invivyd's higher possible upside, analysts clearly believe Invivyd is more favorable than Oculis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oculis	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Invivyd	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Invivyd beats Oculis on 12 of the 16 factors compared between the two stocks.

How does Invivyd compare to Harrow?

Invivyd (NASDAQ:IVVD) and Harrow (NASDAQ:HROW) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, valuation, dividends, earnings and analyst recommendations.

Harrow has a net margin of -5.57% compared to Invivyd's net margin of -138.90%. Harrow's return on equity of 19.59% beat Invivyd's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Invivyd	-138.90%	-53.48%	-41.56%
Harrow	-5.57%	19.59%	2.26%

Harrow has higher revenue and earnings than Invivyd. Harrow is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Invivyd	$53.43M	4.25	-$52.49M	-$0.31	N/A
Harrow	$268.68M	5.22	-$5.14M	-$0.41	N/A

Invivyd currently has a consensus price target of $8.00, suggesting a potential upside of 938.96%. Harrow has a consensus price target of $69.43, suggesting a potential upside of 84.45%. Given Invivyd's higher possible upside, analysts plainly believe Invivyd is more favorable than Harrow.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Invivyd	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Harrow	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

In the previous week, Invivyd had 1 more articles in the media than Harrow. MarketBeat recorded 6 mentions for Invivyd and 5 mentions for Harrow. Harrow's average media sentiment score of 0.92 beat Invivyd's score of 0.88 indicating that Harrow is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Invivyd	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Harrow	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Invivyd has a beta of 0.63, suggesting that its stock price is 37% less volatile than the broader market. Comparatively, Harrow has a beta of 0.28, suggesting that its stock price is 72% less volatile than the broader market.

70.4% of Invivyd shares are held by institutional investors. Comparatively, 72.8% of Harrow shares are held by institutional investors. 12.3% of Invivyd shares are held by company insiders. Comparatively, 12.8% of Harrow shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Harrow beats Invivyd on 11 of the 16 factors compared between the two stocks.

How does Invivyd compare to Hemab Therapeutics?

Hemab Therapeutics (NASDAQ:COAG) and Invivyd (NASDAQ:IVVD) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, risk, media sentiment, profitability and institutional ownership.

Hemab Therapeutics has higher earnings, but lower revenue than Invivyd.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hemab Therapeutics	N/A	N/A	N/A	N/A	N/A
Invivyd	$53.43M	4.25	-$52.49M	-$0.31	N/A

Hemab Therapeutics has a net margin of 0.00% compared to Invivyd's net margin of -138.90%. Hemab Therapeutics' return on equity of 0.00% beat Invivyd's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hemab Therapeutics	N/A	N/A	N/A
Invivyd	-138.90%	-53.48%	-41.56%

Hemab Therapeutics presently has a consensus target price of $41.75, indicating a potential upside of 67.13%. Invivyd has a consensus target price of $8.00, indicating a potential upside of 938.96%. Given Invivyd's higher probable upside, analysts plainly believe Invivyd is more favorable than Hemab Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hemab Therapeutics	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
Invivyd	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Invivyd had 4 more articles in the media than Hemab Therapeutics. MarketBeat recorded 6 mentions for Invivyd and 2 mentions for Hemab Therapeutics. Hemab Therapeutics' average media sentiment score of 0.93 beat Invivyd's score of 0.88 indicating that Hemab Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hemab Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Invivyd	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

70.4% of Invivyd shares are owned by institutional investors. 12.3% of Invivyd shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Hemab Therapeutics beats Invivyd on 6 of the 11 factors compared between the two stocks.

How does Invivyd compare to WAVE Life Sciences?

Invivyd (NASDAQ:IVVD) and WAVE Life Sciences (NASDAQ:WVE) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, dividends, valuation, risk, profitability, earnings and analyst recommendations.

Invivyd has a net margin of -138.90% compared to WAVE Life Sciences' net margin of -255.70%. Invivyd's return on equity of -53.48% beat WAVE Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Invivyd	-138.90%	-53.48%	-41.56%
WAVE Life Sciences	-255.70%	-56.76%	-42.80%

In the previous week, WAVE Life Sciences had 1 more articles in the media than Invivyd. MarketBeat recorded 7 mentions for WAVE Life Sciences and 6 mentions for Invivyd. Invivyd's average media sentiment score of 0.88 beat WAVE Life Sciences' score of 0.88 indicating that Invivyd is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Invivyd	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
WAVE Life Sciences	1 Very Positive mention(s)	4 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

70.4% of Invivyd shares are owned by institutional investors. Comparatively, 89.7% of WAVE Life Sciences shares are owned by institutional investors. 12.3% of Invivyd shares are owned by company insiders. Comparatively, 24.3% of WAVE Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Invivyd presently has a consensus price target of $8.00, suggesting a potential upside of 938.96%. WAVE Life Sciences has a consensus price target of $26.41, suggesting a potential upside of 349.94%. Given Invivyd's higher probable upside, equities research analysts plainly believe Invivyd is more favorable than WAVE Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Invivyd	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
WAVE Life Sciences	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.87

Invivyd has a beta of 0.63, meaning that its stock price is 37% less volatile than the broader market. Comparatively, WAVE Life Sciences has a beta of -1.33, meaning that its stock price is 233% less volatile than the broader market.

Invivyd has higher earnings, but lower revenue than WAVE Life Sciences. WAVE Life Sciences is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Invivyd	$53.43M	4.25	-$52.49M	-$0.31	N/A
WAVE Life Sciences	$71.80M	15.73	-$204.38M	-$1.06	N/A

Summary

Invivyd beats WAVE Life Sciences on 9 of the 16 factors compared between the two stocks.

How does Invivyd compare to Maplight Therapeutics?

Invivyd (NASDAQ:IVVD) and Maplight Therapeutics (NASDAQ:MPLT) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, analyst recommendations, risk, media sentiment, institutional ownership, dividends, valuation and earnings.

70.4% of Invivyd shares are held by institutional investors. 12.3% of Invivyd shares are held by company insiders. Comparatively, 3.8% of Maplight Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Maplight Therapeutics has a net margin of 0.00% compared to Invivyd's net margin of -138.90%. Maplight Therapeutics' return on equity of 0.00% beat Invivyd's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Invivyd	-138.90%	-53.48%	-41.56%
Maplight Therapeutics	N/A	N/A	N/A

In the previous week, Invivyd had 4 more articles in the media than Maplight Therapeutics. MarketBeat recorded 6 mentions for Invivyd and 2 mentions for Maplight Therapeutics. Maplight Therapeutics' average media sentiment score of 0.93 beat Invivyd's score of 0.88 indicating that Maplight Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Invivyd	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Maplight Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Invivyd has higher revenue and earnings than Maplight Therapeutics. Invivyd is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Invivyd	$53.43M	4.25	-$52.49M	-$0.31	N/A
Maplight Therapeutics	N/A	N/A	-$161.15M	-$40.99	N/A

Invivyd currently has a consensus price target of $8.00, indicating a potential upside of 938.96%. Maplight Therapeutics has a consensus price target of $37.78, indicating a potential upside of 36.14%. Given Invivyd's higher probable upside, research analysts clearly believe Invivyd is more favorable than Maplight Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Invivyd	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Maplight Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	3 Strong Buy rating(s)	3.00

Summary

Maplight Therapeutics beats Invivyd on 8 of the 15 factors compared between the two stocks.

Get Invivyd News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IVVD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IVVD vs. The Competition

Export

Metric	Invivyd	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$226.85M	$3.40B	$6.73B	$12.07B
Dividend Yield	N/A	2.25%	2.67%	5.66%
P/E Ratio	-2.48	19.82	24.24	24.42
Price / Sales	4.25	180.35	481.30	88.58
Price / Cash	N/A	123.04	43.54	55.64
Price / Book	0.74	8.32	10.65	6.80
Net Income	-$52.49M	$23.94M	$3.57B	$338.00M
7 Day Performance	-25.24%	3.53%	0.84%	2.68%
1 Month Performance	-33.62%	-2.55%	-0.34%	1.56%
1 Year Performance	-2.78%	44.82%	25.40%	30.59%

Invivyd Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IVVD Invivyd	2.7518 of 5 stars	$0.77 -5.2%	$8.00 +939.0%	-2.8%	$226.85M	$53.43M	N/A	100	Analyst Forecast High Trading Volume
OCS Oculis	3.4662 of 5 stars	$14.51 -36.1%	$40.44 +178.7%	-41.7%	$1.32B	$1.45M	N/A	2	Analyst Forecast High Trading Volume
HROW Harrow	4.3463 of 5 stars	$34.11 -3.1%	$69.43 +103.5%	+24.2%	$1.31B	$268.68M	N/A	180	News Coverage Positive News
COAG Hemab Therapeutics	4.5765 of 5 stars	$27.13 -4.8%	$41.75 +53.9%	N/A	$1.27B	N/A	N/A	72	Quiet Period Expiration
WVE WAVE Life Sciences	3.1071 of 5 stars	$6.26 -4.9%	$27.25 +335.3%	-15.5%	$1.27B	$71.80M	N/A	240	News Coverage Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IVVD) was last updated on 6/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Invivyd (IVVD) Competitors

IVVD vs. OCS, HROW, COAG, WVE, and MPLT

How does Invivyd compare to Oculis?

Summary

How does Invivyd compare to Harrow?

Summary

How does Invivyd compare to Hemab Therapeutics?

Summary

How does Invivyd compare to WAVE Life Sciences?

Summary

How does Invivyd compare to Maplight Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IVVD vs. The Competition

Invivyd Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Invivyd (IVVD) Competitors

IVVD vs. OCS, HROW, COAG, WVE, and MPLT

How does Invivyd compare to Oculis?

Which has better valuation & earnings, OCS or IVVD?

Is OCS or IVVD more profitable?

Does the media favor OCS or IVVD?

Do institutionals & insiders believe in OCS or IVVD?

Which has more volatility and risk, OCS or IVVD?

Do analysts rate OCS or IVVD?

Summary

How does Invivyd compare to Harrow?

Is IVVD or HROW more profitable?

Which has better valuation & earnings, IVVD or HROW?

Do analysts prefer IVVD or HROW?

Does the media prefer IVVD or HROW?

Which has more risk and volatility, IVVD or HROW?

Do insiders & institutionals have more ownership in IVVD or HROW?

Summary

How does Invivyd compare to Hemab Therapeutics?

Which has better earnings and valuation, COAG or IVVD?

Is COAG or IVVD more profitable?

Do analysts recommend COAG or IVVD?

Does the media favor COAG or IVVD?

Do institutionals & insiders believe in COAG or IVVD?

Summary

How does Invivyd compare to WAVE Life Sciences?

Is IVVD or WVE more profitable?

Does the media refer more to IVVD or WVE?

Do insiders & institutionals hold more shares of IVVD or WVE?

Do analysts rate IVVD or WVE?

Which has more volatility & risk, IVVD or WVE?

Which has higher valuation and earnings, IVVD or WVE?

Summary

How does Invivyd compare to Maplight Therapeutics?

Do institutionals & insiders believe in IVVD or MPLT?

Is IVVD or MPLT more profitable?

Does the media refer more to IVVD or MPLT?

Which has stronger earnings and valuation, IVVD or MPLT?

Do analysts rate IVVD or MPLT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IVVD vs. The Competition

Invivyd Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools